{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:50:36Z","timestamp":1791946236304,"version":"4.3.4"},"reference-count":180,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":413,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000098","name":"NIH Clinical Center","doi-asserted-by":"publisher","award":["R01 NS111990"],"award-info":[{"award-number":["R01 NS111990"]}],"id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Angel Fund for ALS Research"},{"name":"ALSOne"},{"name":"ALS Finding a Cure"},{"name":"The Cellucci Fund for ALS Research"},{"name":"The Pierre de Bourgknecht ALS Research Fund"},{"name":"Max Rosenfeld Fund"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s13311-022-01285-w","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T16:05:31Z","timestamp":1662480331000},"page":"1159-1179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Approaches to Gene Modulation Therapy for ALS"],"prefix":"10.1016","volume":"19","author":[{"given":"Katharina E.","family":"Meijboom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1007\/s13311-022-01285-w_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1750-1172-4-3","article-title":"Amyotrophic lateral sclerosis","volume":"4","author":"Wijesekera","year":"2009","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1007\/s13311-022-01285-w_bib2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13024-022-00525-z","article-title":"The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS\/FTD","volume":"17","author":"Masrori","year":"2022","journal-title":"Mol Neurodegener"},{"issue":"15","key":"10.1007\/s13311-022-01285-w_bib3","doi-asserted-by":"crossref","first-page":"708181","DOI":"10.3389\/fncel.2021.708181","article-title":"RNA is a double-edged sword in ALS pathogenesis","volume":"19","author":"Zaepfel","year":"2021","journal-title":"Front Cell Neurosci"},{"issue":"12","key":"10.1007\/s13311-022-01285-w_bib4","doi-asserted-by":"crossref","first-page":"6352","DOI":"10.3390\/ijms22126352","article-title":"The link between oxidative stress, redox status, bioenergetics and mitochondria in the pathophysiology of ALS","volume":"22","author":"Obrador","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1007\/s13311-022-01285-w_bib5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.nbd.2017.02.004","article-title":"Neurobiology of axonal transport defects in motor neuron diseases: opportunities for translational research?","volume":"105","author":"De Vos","year":"2017","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-022-01285-w_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.nbd.2018.07.005","article-title":"Autophagy and mitophagy in ALS","volume":"122","author":"Evans","year":"2019","journal-title":"Neurobiol Dis"},{"issue":"Pt 1","key":"10.1007\/s13311-022-01285-w_bib7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.expneurol.2015.09.019","article-title":"Excitotoxicity in ALS: overstimulation, or overreaction?","volume":"275","author":"King","year":"2016","journal-title":"Exp Neurol"},{"key":"10.1007\/s13311-022-01285-w_bib8","doi-asserted-by":"crossref","unstructured":"Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci [Internet]. 2019 [cited 2022 Mar 15];13. Available from: https:\/\/www.frontiersin.org\/article\/10.3389\/fnins.2019.01310.","DOI":"10.3389\/fnins.2019.01310"},{"issue":"4","key":"10.1007\/s13311-022-01285-w_bib9","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s12640-018-9980-5","article-title":"Fungal neurotoxins and sporadic amyotrophic lateral sclerosis","volume":"35","author":"French","year":"2019","journal-title":"Neurotox Res"},{"issue":"75","key":"10.1007\/s13311-022-01285-w_bib10","article-title":"Unraveling the complex interplay between genes, environment, and climate in ALS","volume":"30","author":"Vasta","year":"2021","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1007\/s13311-022-01285-w_bib11","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1172\/JCI82693","article-title":"Emerging mechanisms of molecular pathology in ALS","volume":"125","author":"Peters","year":"2015","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1007\/s13311-022-01285-w_bib12","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/WCO.0000000000000737","article-title":"Update on amyotrophic lateral sclerosis genetics","volume":"32","author":"Brenner","year":"2019","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"10.1007\/s13311-022-01285-w_bib13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/15548627.2019.1644076","article-title":"ALS-FTLD-linked mutations of SQSTM1\/p62 disrupt selective autophagy and NFE2L2\/NRF2 anti-oxidative stress pathway","volume":"16","author":"Deng","year":"2020","journal-title":"Autophagy"},{"issue":"6","key":"10.1007\/s13311-022-01285-w_bib14","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/jnnp.2010.224501","article-title":"Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"82","author":"Byrne","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1007\/s13311-022-01285-w_bib15","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/braincomms\/fcab242","article-title":"Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective","volume":"3","author":"Wong","year":"2021","journal-title":"Brain Commun."},{"issue":"1","key":"10.1007\/s13311-022-01285-w_bib16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1755-5949.2009.00116.x","article-title":"A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?","volume":"17","author":"Bellingham","year":"2011","journal-title":"CNS Neurosci Ther"},{"issue":"12","key":"10.1007\/s13311-022-01285-w_bib17","doi-asserted-by":"crossref","first-page":"E319","DOI":"10.1503\/cmaj.191236","article-title":"Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics","volume":"192","author":"Breiner","year":"2020","journal-title":"CMAJ Can Med Assoc J J Assoc Medicale Can"},{"issue":"6415","key":"10.1007\/s13311-022-01285-w_bib18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/362059a0","article-title":"Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis","volume":"362","author":"Rosen","year":"1993","journal-title":"Nature"},{"issue":"18","key":"10.1007\/s13311-022-01285-w_bib19","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.3390\/ijms21186807","article-title":"Clinical and molecular landscape of ALS patients with SOD1 mutations: novel pathogenic variants and novel phenotypes. A single ALS center study","volume":"21","author":"Bernard","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1007\/s13311-022-01285-w_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0003-9861(86)90526-6","article-title":"Biological effects of the superoxide radical","volume":"247","author":"Fridovich","year":"1986","journal-title":"Arch Biochem Biophys"},{"key":"10.1007\/s13311-022-01285-w_bib21","unstructured":"ALSoD [Internet]. [cited 2022 Mar 21]. Available from: https:\/\/alsod.ac.uk\/output\/gene.php\/SOD1."},{"issue":"4","key":"10.1007\/s13311-022-01285-w_bib22","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40035-015-0036-y","article-title":"Genotype-phenotype relationship in hereditary amyotrophic lateral sclerosis","volume":"24","author":"Yamashita","year":"2015","journal-title":"Transl Neurodegener"},{"issue":"6555","key":"10.1007\/s13311-022-01285-w_bib23","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/378342a0","article-title":"Toxic mutants in Charcot's sclerosis","volume":"378","author":"Cleveland","year":"1995","journal-title":"Nature"},{"issue":"60","key":"10.1007\/s13311-022-01285-w_bib24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jbior.2015.10.006","article-title":"SOD1 in neurotoxicity and its controversial roles in SOD1 mutation-negative ALS","volume":"1","author":"Hayashi","year":"2016","journal-title":"Adv Biol Regul"},{"issue":"5166","key":"10.1007\/s13311-022-01285-w_bib25","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1126\/science.8209258","article-title":"Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation","volume":"264","author":"Gurney","year":"1994","journal-title":"Science"},{"issue":"2","key":"10.1007\/s13311-022-01285-w_bib26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0896-6273(00)80272-X","article-title":"ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions","volume":"18","author":"Bruijn","year":"1997","journal-title":"Neuron"},{"issue":"8","key":"10.1007\/s13311-022-01285-w_bib27","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1093\/brain\/awt097","article-title":"Is SOD1 loss of function involved in amyotrophic lateral sclerosis?","volume":"136","author":"Saccon","year":"2013","journal-title":"Brain"},{"issue":"5","key":"10.1007\/s13311-022-01285-w_bib28","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1056\/NEJMc1905039","article-title":"Phenotype in an infant with SOD1 homozygous truncating mutation","volume":"381","author":"Andersen","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1007\/s13311-022-01285-w_bib29","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1093\/brain\/awz182","article-title":"SOD1 deficiency: a novel syndrome distinct from amyotrophic lateral sclerosis","volume":"142","author":"Park","year":"2019","journal-title":"Brain"},{"issue":"2","key":"10.1007\/s13311-022-01285-w_bib30","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/jmg.35.2.174","article-title":"Homozygosity for Asn86Ser mutation in the CuZn-superoxide dismutase gene produces a severe clinical phenotype in a juvenile onset case of familial amyotrophic lateral sclerosis","volume":"35","author":"Hayward","year":"1998","journal-title":"J Med Genet"},{"issue":"3","key":"10.1007\/s13311-022-01285-w_bib31","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbrc.2006.10.093","article-title":"TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"351","author":"Arai","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"5796","key":"10.1007\/s13311-022-01285-w_bib32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1126\/science.1134108","article-title":"Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"314","author":"Neumann","year":"2006","journal-title":"Science"},{"issue":"7","key":"10.1007\/s13311-022-01285-w_bib33","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/jnnp-2016-315018","article-title":"Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"88","author":"Zou","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7899","key":"10.1007\/s13311-022-01285-w_bib34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41586-022-04424-7","article-title":"TDP-43 represses cryptic exon inclusion in the FTD\u2013ALS gene UNC13A","volume":"603","author":"Ma","year":"2022","journal-title":"Nature"},{"issue":"5","key":"10.1007\/s13311-022-01285-w_bib35","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.neuron.2020.08.022","article-title":"ALS genetics: gains, losses, and implications for future therapies","volume":"108","author":"Kim","year":"2020","journal-title":"Neuron"},{"issue":"9","key":"10.1007\/s13311-022-01285-w_bib36","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.3390\/ijms22094705","article-title":"Molecular mechanisms underlying tdp-43 pathology in cellular and animal models of ALS and FTLD","volume":"22","author":"Wood","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"16","key":"10.1007\/s13311-022-01285-w_bib37","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1093\/hmg\/ddu152","article-title":"Distinct pathways leading to TDP-43-induced cellular dysfunctions","volume":"23","author":"Yamashita","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1007\/s13311-022-01285-w_bib38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12035-013-8427-5","article-title":"Overexpression of ALS-associated p.M337V human TDP-43 in mice worsens disease features compared to wild-type human TDP-43 mice","volume":"48","author":"Janssens","year":"2013","journal-title":"Mol Neurobiol"},{"issue":"5918","key":"10.1007\/s13311-022-01285-w_bib39","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1126\/science.1166066","article-title":"Mutations in the FUS\/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis","volume":"323","author":"Kwiatkowski","year":"2009","journal-title":"Science"},{"issue":"5918","key":"10.1007\/s13311-022-01285-w_bib40","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.1165942","article-title":"Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6","volume":"323","author":"Vance","year":"2009","journal-title":"Science"},{"issue":"8","key":"10.1007\/s13311-022-01285-w_bib41","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1177\/0883073820915099","article-title":"The occurrence of FUS mutations in pediatric amyotrophic lateral sclerosis: a case report and review of the literature","volume":"35","author":"Picher-Martel","year":"2020","journal-title":"J Child Neurol"},{"key":"10.1007\/s13311-022-01285-w_bib42","doi-asserted-by":"crossref","unstructured":"Buratti E. Trends in understanding the pathological roles of TDP-43 and FUS proteins. In: Ghetti B, Buratti E, Boeve B, Rademakers R, editors. Frontotemporal Dementias : Emerging Milestones of the 21st Century [Internet]. Cham: Springer International Publishing; 2021 [cited 2022 Mar 27]. p. 243\u201367. (Adv Exp Med Biol). Available from: https:\/\/doi.org\/10.1007\/978-3-030-51140-1_15.","DOI":"10.1007\/978-3-030-51140-1_15"},{"key":"10.1007\/s13311-022-01285-w_bib43","unstructured":"ALSoD [Internet]. [cited 2022 Mar 26]. Available from: https:\/\/alsod.ac.uk\/output\/gene.php\/FUS."},{"issue":"9","key":"10.1007\/s13311-022-01285-w_bib44","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1093\/brain\/awz217","article-title":"Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis","volume":"142","author":"Tyzack","year":"2019","journal-title":"Brain"},{"key":"10.1007\/s13311-022-01285-w_bib45","doi-asserted-by":"crossref","unstructured":"Notaro A, Messina A, La Bella V. A deletion of the nuclear localization signal domain in the Fus protein induces stable post-stress cytoplasmic inclusions in SH-SY5Y cells. Front Neurosci [Internet]. 2021 [cited 2022 Mar 27];15. Available from: https:\/\/www.frontiersin.org\/article\/10.3389\/fnins.2021.759659.","DOI":"10.3389\/fnins.2021.759659"},{"issue":"10","key":"10.1007\/s13311-022-01285-w_bib46","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.15252\/embj.201592559","article-title":"Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss","volume":"35","author":"Scekic-Zahirovic","year":"2016","journal-title":"EMBO J"},{"issue":"5","key":"10.1007\/s13311-022-01285-w_bib47","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3389\/fmolb.2018.00044","article-title":"Importance of functional loss of FUS in FTLD\/ALS","volume":"3","author":"Ishigaki","year":"2018","journal-title":"Front Mol Biosci"},{"issue":"2","key":"10.1007\/s13311-022-01285-w_bib48","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","article-title":"Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS","volume":"72","author":"DeJesus-Hernandez","year":"2011","journal-title":"Neuron"},{"issue":"4","key":"10.1007\/s13311-022-01285-w_bib49","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1474-4422(12)70043-1","article-title":"Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study","volume":"11","author":"Majounie","year":"2012","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1007\/s13311-022-01285-w_bib50","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","article-title":"A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD","volume":"72","author":"Renton","year":"2011","journal-title":"Neuron"},{"issue":"3","key":"10.1007\/s13311-022-01285-w_bib51","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jamaneurol.2013.6002","article-title":"Frontotemporal dementia associated with the C9ORF72 mutation: a unique clinical profile","volume":"71","author":"Devenney","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-022-01285-w_bib52","doi-asserted-by":"crossref","unstructured":"Van Mossevelde S, van der Zee J, Cruts M, Van Broeckhoven C. Relationship between C9orf72 repeat size and clinical phenotype. Vol. 44, Current Opinion in Genetics and Development. Elsevier Ltd; 2017. p. 117\u201324.","DOI":"10.1016\/j.gde.2017.02.008"},{"issue":"1","key":"10.1007\/s13311-022-01285-w_bib53","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s40478-019-0724-4","article-title":"C9orf72 intermediate expansions of 24\u201330 repeats are associated with ALS","volume":"7","author":"Iacoangeli","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"10.1007\/s13311-022-01285-w_bib54","doi-asserted-by":"crossref","unstructured":"Amick J, Ferguson SM. C9orf72: at the intersection of lysosome cell biology and neurodegenerative disease. Vol. 18, Traffic. Blackwell Munksgaard; 2017. p. 267\u201376.","DOI":"10.1111\/tra.12477"},{"issue":"3","key":"10.1007\/s13311-022-01285-w_bib55","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm.4490","article-title":"Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS\/FTD human induced motor neurons","volume":"24","author":"Shi","year":"2018","journal-title":"Nat Med"},{"issue":"5","key":"10.1007\/s13311-022-01285-w_bib56","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41593-020-0619-5","article-title":"Reduced C9ORF72 function exacerbates gain of toxicity from ALS\/FTD-causing repeat expansion in C9orf72","volume":"23","author":"Zhu","year":"2020","journal-title":"Nat Neurosci"},{"issue":"6","key":"10.1007\/s13311-022-01285-w_bib57","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00401-013-1200-z","article-title":"C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci","volume":"126","author":"Mizielinska","year":"2013","journal-title":"Acta Neuropathol (Berl)"},{"issue":"6","key":"10.1007\/s13311-022-01285-w_bib58","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00401-013-1192-8","article-title":"Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD\/ALS","volume":"126","author":"Gendron","year":"2013","journal-title":"Acta Neuropathol (Berl)"},{"issue":"6125","key":"10.1007\/s13311-022-01285-w_bib59","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1126\/science.1232927","article-title":"The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD\/ALS","volume":"339","author":"Mori","year":"2013","journal-title":"Science"},{"issue":"51","key":"10.1007\/s13311-022-01285-w_bib60","doi-asserted-by":"crossref","first-page":"E4968","DOI":"10.1073\/pnas.1315438110","article-title":"RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia","volume":"110","author":"Zu","year":"2013","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"10.1007\/s13311-022-01285-w_bib61","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.neuron.2013.02.004","article-title":"Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD\/ALS","volume":"77","author":"Ash","year":"2013","journal-title":"Neuron"},{"issue":"4","key":"10.1007\/s13311-022-01285-w_bib62","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00401-014-1329-4","article-title":"C9orf72 FTLD\/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration","volume":"128","author":"May","year":"2014","journal-title":"Acta Neuropathol (Berl)"},{"issue":"6","key":"10.1007\/s13311-022-01285-w_bib63","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.neuron.2014.12.010","article-title":"Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS\/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death","volume":"84","author":"Wen","year":"2014","journal-title":"Neuron"},{"issue":"1","key":"10.1007\/s13311-022-01285-w_bib64","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1038\/s41467-020-17129-0","article-title":"C9orf72 arginine-rich dipeptide repeats inhibit UPF1-mediated RNA decay via translational repression","volume":"11","author":"Sun","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1007\/s13311-022-01285-w_bib65","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s40478-020-01028-y","article-title":"Co-expression of C9orf72 related dipeptide-repeats over 1000 repeat units reveals age- and combination-specific phenotypic profiles in Drosophila","volume":"8","author":"West","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"10.1007\/s13311-022-01285-w_bib66","doi-asserted-by":"crossref","unstructured":"Zhang YJ, Guo L, Gonzales PK, Gendron TF, Wu Y, Jansen-West K, et al. Heterochromatin anomalies and double-stranded RNA accumulation underlie C9orf72 poly(PR) toxicity. Science. 2019;363(6428).","DOI":"10.1126\/science.aav2606"},{"issue":"8","key":"10.1007\/s13311-022-01285-w_bib67","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41591-018-0071-1","article-title":"Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis","volume":"24","author":"Zhang","year":"2018","journal-title":"Nat Med"},{"key":"10.1007\/s13311-022-01285-w_bib68","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1016\/S0040-4039(01)89794-X","article-title":"Synthesis of ribonucleosides and diribonucleoside phosphates containing 2-chloroethylamine and nitrogen mustard residues","volume":"37","author":"Belikova","year":"1967","journal-title":"Tetrahedron Lett"},{"key":"10.1007\/s13311-022-01285-w_bib69","doi-asserted-by":"crossref","unstructured":"Migliorati JM, Liu S, Liu A, Gogate A, Nair S, Bahal R, et al. Absorption, distribution, metabolism, and excretion of FDA-approved antisense oligonucleotide drugs. Drug Metab Dispos [Internet]. 2022 Jan 1 [cited 2022 Mar 21]; Available from: https:\/\/dmd.aspetjournals.org\/content\/early\/2022\/02\/27\/dmd.121.000417.","DOI":"10.1096\/fasebj.2022.36.S1.R5892"},{"issue":"70","key":"10.1007\/s13311-022-01285-w_bib70","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic antisense oligonucleotides are coming of age","volume":"27","author":"Bennett","year":"2019","journal-title":"Annu Rev Med"},{"issue":"10","key":"10.1007\/s13311-022-01285-w_bib71","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1073\/pnas.91.10.4155","article-title":"Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons","volume":"91","author":"Rothstein","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"10.1007\/s13311-022-01285-w_bib72","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1073\/pnas.91.14.6384","article-title":"Down-regulation of copper\/zinc superoxide dismutase causes apoptotic death in PC12 neuronal cells","volume":"91","author":"Troy","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1007\/s13311-022-01285-w_bib73","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","article-title":"Antisense oligonucleotide therapy for neurodegenerative disease","volume":"116","author":"Smith","year":"2006","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1007\/s13311-022-01285-w_bib74","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","article-title":"An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study","volume":"12","author":"Miller","year":"2013","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1007\/s13311-022-01285-w_bib75","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1172\/JCI99081","article-title":"Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models","volume":"128","author":"McCampbell","year":"2018","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1007\/s13311-022-01285-w_bib76","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1\u20132 trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-022-01285-w_bib77","unstructured":"Miller T, Cudkowicz M. Results from the Phase 3 VALOR study and its open-label extension: evaluating the clinical efficacy and safety of tofersen in adults with ALS and confirmed SOD1 mutation [Internet]. Published online October 19, 2021. Available from: https:\/\/biogen.gcs-web.com\/static-files\/b2154d4e-f69f-49d4-9a61-e834387293ea. Accessed 1 Apr 2022."},{"key":"10.1007\/s13311-022-01285-w_bib78","unstructured":"Biogen announces topline results from the tofersen phase 3 Study and its open-label extension in SOD1-ALS | Biogen [Internet]. Published online October 17, 2021. Available from: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-announces-topline-results-tofersen-phase-3-study-and-its. Accessed 2 April 2022."},{"key":"10.1007\/s13311-022-01285-w_bib79","unstructured":"Biogen. A phase 3 randomized, placebo-controlled trial with a longitudinal natural history run-in and open-label extension to evaluate BIIB067 initiated in clinically presymptomatic adults with a confirmed superoxide dismutase 1 mutation [Internet]. clinicaltrials.gov; 2022 Mar [cited 2022 Mar 31]. Report No.: NCT04856982. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04856982."},{"issue":"208","key":"10.1007\/s13311-022-01285-w_bib80","doi-asserted-by":"crossref","first-page":"208ra149","DOI":"10.1126\/scitranslmed.3007529","article-title":"Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion","volume":"5","author":"Sareen","year":"2013","journal-title":"Sci Transl Med."},{"issue":"2","key":"10.1007\/s13311-022-01285-w_bib81","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.neuron.2013.10.015","article-title":"RNA toxicity from the ALS\/FTD C9ORF72 expansion is mitigated by antisense intervention","volume":"80","author":"Donnelly","year":"2013","journal-title":"Neuron"},{"issue":"5","key":"10.1007\/s13311-022-01285-w_bib82","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.neuron.2015.10.027","article-title":"C9orf72 BAC transgenic mice display typical pathologic features of ALS\/FTD","volume":"88","author":"O'Rourke","year":"2015","journal-title":"Neuron"},{"key":"10.1007\/s13311-022-01285-w_bib83","doi-asserted-by":"crossref","unstructured":"Lagier-Tourenne C, Baughn M, Rigo F, Sun S, Liu P, Li HR, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A. 2013;110(47).","DOI":"10.1073\/pnas.1318835110"},{"issue":"3","key":"10.1007\/s13311-022-01285-w_bib84","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.neuron.2016.04.006","article-title":"Gain of toxicity from ALS\/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs","volume":"90","author":"Jiang","year":"2016","journal-title":"Neuron"},{"issue":"559","key":"10.1007\/s13311-022-01285-w_bib85","doi-asserted-by":"crossref","first-page":"eabb3774","DOI":"10.1126\/scitranslmed.abb3774","article-title":"C9orf72 poly(GR) aggregation induces TDP-43 proteinopathy","volume":"12","author":"Cook","year":"2020","journal-title":"Sci Transl Med."},{"issue":"12","key":"10.1007\/s13311-022-01285-w_bib86","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/s41467-021-21112-8","article-title":"Variant-selective stereopure oligonucleotides protect against pathologies associated with C9orf72-repeat expansion in preclinical models","volume":"8","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1007\/s13311-022-01285-w_bib87","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/brain\/awx024","article-title":"C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia","volume":"140","author":"Aoki","year":"2017","journal-title":"Brain"},{"issue":"1","key":"10.1007\/s13311-022-01285-w_bib88","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41591-021-01557-6","article-title":"Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide","volume":"28","author":"Tran","year":"2022","journal-title":"Nat Med"},{"key":"10.1007\/s13311-022-01285-w_bib89","unstructured":"Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis | Biogen [Internet]. Published online March 28, 2022. Available from: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-and-ionis-announce-topline-phase-1-study-results. Accessed 6 Apr 2022."},{"key":"10.1007\/s13311-022-01285-w_bib90","doi-asserted-by":"crossref","unstructured":"Liu Y, Andreucci A, Iwamoto N, Yin Y, Yang H, Liu F, et al. WVE-004, an investigational stereopure antisense oligonucleotide for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (2302). Neurology [Internet]. 2021 Apr 13 [cited 2022 Apr 7];96(15 Supplement). Available from: https:\/\/n.neurology.org\/content\/96\/15_Supplement\/2302.","DOI":"10.1212\/WNL.96.15_supplement.2302"},{"issue":"1","key":"10.1007\/s13311-022-01285-w_bib91","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","article-title":"Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis","volume":"28","author":"Korobeynikov","year":"2022","journal-title":"Nat Med"},{"key":"10.1007\/s13311-022-01285-w_bib92","unstructured":"Promising ALS Therapy Moves Closer to Clinic [Internet]. Columbia University Irving Medical Center. Published online January 24, 2022. Available from: https:\/\/www.cuimc.columbia.edu\/news\/promising-als-therapy-moves-closer-clinic. Accessed 9 Apr 2022."},{"key":"10.1007\/s13311-022-01285-w_bib93","unstructured":"Ionis Pharmaceuticals, Inc. A phase 1-3 study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of intrathecally administered ION363 in amyotrophic lateral sclerosis patients with fused in sarcoma mutations (FUS-ALS) [Internet]. clinicaltrials.gov; 2022 Mar [cited 2022 Apr 7]. Report No.: NCT04768972. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04768972."},{"issue":"7310","key":"10.1007\/s13311-022-01285-w_bib94","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nature09320","article-title":"Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS","volume":"466","author":"Elden","year":"2010","journal-title":"Nature"},{"issue":"7650","key":"10.1007\/s13311-022-01285-w_bib95","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nature22038","article-title":"Therapeutic reduction of ataxin 2 extends lifespan and reduces pathology in TDP-43 mice","volume":"544","author":"Becker","year":"2017","journal-title":"Nature"},{"key":"10.1007\/s13311-022-01285-w_bib96","unstructured":"Biogen. A phase 1 multiple-ascending-dose study to assess the safety, tolerability, and pharmacokinetics of BIIB105 administered intrathecally to adults with amyotrophic lateral sclerosis with or without Poly-CAG expansion in the ataxin-2 gene [Internet]. clinicaltrials.gov; 2022 Jan [cited 2022 Apr 10]. Report No.: NCT04494256. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04494256."},{"issue":"3","key":"10.1007\/s13311-022-01285-w_bib97","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1046\/j.1471-4159.2003.02053.x","article-title":"Antisense peptide nucleic acid-mediated knockdown of the p75 neurotrophin receptor delays motor neuron disease in mutant SOD1 transgenic mice","volume":"87","author":"Turner","year":"2003","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-022-01285-w_bib98","doi-asserted-by":"crossref","first-page":"845345","DOI":"10.1155\/2013\/845345","article-title":"Presymptomatic treatment with acetylcholinesterase antisense oligonucleotides prolongs survival in ALS (G93A-SOD1) mice","volume":"2013","author":"Marc","year":"2013","journal-title":"BioMed Res Int"},{"issue":"20","key":"10.1007\/s13311-022-01285-w_bib99","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1093\/hmg\/ddt261","article-title":"Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice","volume":"22","author":"Koval","year":"2013","journal-title":"Hum Mol Genet"},{"issue":"307","key":"10.1007\/s13311-022-01285-w_bib100","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.expneurol.2018.06.009","article-title":"Antagonizing bone morphogenetic protein 4 attenuates disease progression in a rat model of amyotrophic lateral sclerosis","volume":"1","author":"Shijo","year":"2018","journal-title":"Exp Neurol"},{"issue":"6","key":"10.1007\/s13311-022-01285-w_bib101","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.neuron.2021.12.019","article-title":"Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis","volume":"110","author":"Zhang","year":"2022","journal-title":"Neuron"},{"issue":"3","key":"10.1007\/s13311-022-01285-w_bib102","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4155\/tde-2018-0061","article-title":"Developing small activating RNA as a therapeutic: current challenges and promises","volume":"10","author":"Kwok","year":"2019","journal-title":"Ther Deliv"},{"issue":"16","key":"10.1007\/s13311-022-01285-w_bib103","doi-asserted-by":"crossref","first-page":"22893","DOI":"10.18632\/oncotarget.8290","article-title":"Enhancing DPYSL3 gene expression via a promoter-targeted small activating RNA approach suppresses cancer cell motility and metastasis","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1007\/s13311-022-01285-w_bib104","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nsmb.1444","article-title":"Antisense transcripts are targets for activating small RNAs","volume":"15","author":"Schwartz","year":"2008","journal-title":"Nat Struct Mol Biol"},{"issue":"15","key":"10.1007\/s13311-022-01285-w_bib105","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-20-0414","article-title":"MTL-CEBPA, a small activating RNA therapeutic upregulating C\/EBP-\u03b1, in patients with advanced liver cancer: a first-in-human, multicenter, open-label, phase i trial","volume":"26","author":"Sarker","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"6","key":"10.1007\/s13311-022-01285-w_bib106","doi-asserted-by":"crossref","first-page":"39311","DOI":"10.1038\/srep39311","article-title":"RNA activation of haploinsufficient Foxg1 gene in murine neocortex","volume":"20","author":"Fimiani","year":"2016","journal-title":"Sci Rep"},{"key":"10.1007\/s13311-022-01285-w_bib107","first-page":"1","article-title":"Endogenous ADAR-mediated RNA editing in non-human primates using stereopure chemically modified oligonucleotides","volume":"7","author":"Monian","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1007\/s13311-022-01285-w_bib108","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.nbd.2011.12.033","article-title":"Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons","volume":"45","author":"Hideyama","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-022-01285-w_bib109","unstructured":"ALSoD [Internet]. [cited 2022 Apr 25]. Available from: https:\/\/alsod.ac.uk\/output\/gene.php\/TARDBP."},{"issue":"6","key":"10.1007\/s13311-022-01285-w_bib110","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1073\/pnas.55.6.1467","article-title":"Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics","volume":"55","author":"Hoggan","year":"1966","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1007\/s13311-022-01285-w_bib111","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1007\/s13311-022-01285-w_bib112","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1038\/s41598-021-82599-1","article-title":"Comprehensive characterization and quantification of adeno associated vectors by size exclusion chromatography and multi angle light scattering","volume":"11","author":"McIntosh","year":"2021","journal-title":"Sci Rep"},{"issue":"17","key":"10.1007\/s13311-022-01285-w_bib113","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1089\/hum.1996.7.17-2101","article-title":"Quantitative analysis of the packaging capacity of recombinant adeno-associated virus","volume":"7","author":"Dong","year":"1996","journal-title":"Hum Gene Ther"},{"issue":"11","key":"10.1007\/s13311-022-01285-w_bib114","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/gt.2008.55","article-title":"Adeno-associated virus integration: virus versus vector","volume":"15","author":"Smith","year":"2008","journal-title":"Gene Ther"},{"issue":"1","key":"10.1007\/s13311-022-01285-w_bib115","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/s41467-019-12449-2","article-title":"High levels of AAV vector integration into CRISPR-induced DNA breaks","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat Commun"},{"issue":"22","key":"10.1007\/s13311-022-01285-w_bib116","doi-asserted-by":"crossref","first-page":"10613","DOI":"10.1073\/pnas.90.22.10613","article-title":"Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector","volume":"90","author":"Flotte","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-022-01285-w_bib117","doi-asserted-by":"crossref","unstructured":"Flotte T, Carter B, Conrad C, Guggino W, Reynolds T, Rosenstein B, et al. A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Johns Hopkins Children's Center, Baltimore, Maryland. Hum Gene Ther. 1996 Jun 10;7(9):1145\u201359.","DOI":"10.1089\/hum.1996.7.9-1145"},{"issue":"1","key":"10.1007\/s13311-022-01285-w_bib118","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat Biotechnol"},{"issue":"8","key":"10.1007\/s13311-022-01285-w_bib119","first-page":"36","article-title":"Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice","volume":"28","author":"Tanguy","year":"2015","journal-title":"Front Mol Neurosci"},{"issue":"18","key":"10.1007\/s13311-022-01285-w_bib120","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1007\/s13311-022-01285-w_bib121","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/mt.2013.211","article-title":"Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS","volume":"21","author":"Foust","year":"2013","journal-title":"Mol Ther"},{"issue":"12","key":"10.1007\/s13311-022-01285-w_bib122","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.omtn.2018.04.015","article-title":"Translating SOD1 gene silencing toward the clinic: a highly efficacious, off-target-free, and biomarker-supported strategy for fALS","volume":"3","author":"Iannitti","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"issue":"47","key":"10.1007\/s13311-022-01285-w_bib123","doi-asserted-by":"crossref","first-page":"15587","DOI":"10.1523\/JNEUROSCI.2037-14.2014","article-title":"Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex","volume":"34","author":"Thomsen","year":"2014","journal-title":"J Neurosci Off J Soc Neurosci"},{"issue":"1","key":"10.1007\/s13311-022-01285-w_bib124","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/hum.2015.122","article-title":"Therapeutic rAAVrh10 mediated SOD1 silencing in adult SOD1G93A mice and nonhuman primates","volume":"27","author":"Borel","year":"2016","journal-title":"Hum Gene Ther"},{"issue":"4","key":"10.1007\/s13311-022-01285-w_bib125","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ana.24618","article-title":"Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model","volume":"79","author":"Stoica","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01285-w_bib126","doi-asserted-by":"crossref","unstructured":"Borel F, Gernoux G, Sun H, Stock R, Blackwood M, Brown RH, et al. Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci Transl Med. 2018;10(465).","DOI":"10.1126\/scitranslmed.aau6414"},{"issue":"2","key":"10.1007\/s13311-022-01285-w_bib127","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 suppression with adeno-associated virus and microRNA in familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1007\/s13311-022-01285-w_bib128","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/hmg\/ddt454","article-title":"Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis","volume":"23","author":"Wang","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"17","key":"10.1007\/s13311-022-01285-w_bib129","first-page":"246","article-title":"Intralingual and intrapleural AAV gene therapy prolongs survival in a SOD1 ALS mouse model","volume":"24","author":"Keeler","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"9","key":"10.1007\/s13311-022-01285-w_bib130","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.ymthe.2017.05.017","article-title":"A new AAV10-U7-mediated gene therapy prolongs survival and restores function in an ALS mouse model","volume":"25","author":"Biferi","year":"2017","journal-title":"Mol Ther"},{"issue":"3\u20134","key":"10.1007\/s13311-022-01285-w_bib131","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41434-019-0116-1","article-title":"The deletion of mutant SOD1 via CRISPR\/Cas9\/sgRNA prolongs survival in an amyotrophic lateral sclerosis mouse model","volume":"27","author":"Duan","year":"2020","journal-title":"Gene Ther"},{"issue":"12","key":"10.1007\/s13311-022-01285-w_bib132","doi-asserted-by":"crossref","first-page":"eaar3952","DOI":"10.1126\/sciadv.aar3952","article-title":"In vivo genome editing improves motor function and extends survival in a mouse model of ALS","volume":"3","author":"Gaj","year":"2017","journal-title":"Sci Adv"},{"issue":"5","key":"10.1007\/s13311-022-01285-w_bib133","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s13238-017-0397-3","article-title":"CRISPR\/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs","volume":"8","author":"Wang","year":"2017","journal-title":"Protein Cell"},{"issue":"3","key":"10.1007\/s13311-022-01285-w_bib134","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/mt.2013.239","article-title":"Adeno-associated virus\u2013mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis","volume":"22","author":"Patel","year":"2014","journal-title":"Mol Ther"},{"issue":"56","key":"10.1007\/s13311-022-01285-w_bib135","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.nbd.2013.04.007","article-title":"Single chain variable fragment antibodies block aggregation and toxicity induced by familial ALS-linked mutant forms of SOD1","volume":"1","author":"Ghadge","year":"2013","journal-title":"Neurobiol Dis"},{"issue":"121","key":"10.1007\/s13311-022-01285-w_bib136","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.nbd.2018.08.021","article-title":"Single chain variable fragment antibodies directed against SOD1 ameliorate disease in mutant SOD1 transgenic mice","volume":"1","author":"Ghadge","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-022-01285-w_bib137","unstructured":"Statement from Novartis Gene Therapies: OAV301 program for familial ALS caused by SOD1 mutation [Internet]. Les Turner ALS Foundation. Published online November 30, 2020. Available from: https:\/\/lesturnerals.org\/oav301-program-for-familial-als-caused-by-sod1-mutation-statement-from-novartis-gene-therapies\/. Accessed 19 Apr 2022."},{"key":"10.1007\/s13311-022-01285-w_bib138","unstructured":"By. Apic Bio Receives FDA Fast Track Designation for APB-102 | Apic Bio [Internet]. Published online July 28, 2021. Available from: https:\/\/apic-bio.com\/apic-bio-receives-fda-fast-track-designation-for-apb-102-for-the-treatment-of-patients-with-sod1-als\/. Accessed 20 Apr 2022."},{"issue":"4","key":"10.1007\/s13311-022-01285-w_bib139","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ymthe.2020.01.005","article-title":"Treatment of a mouse model of ALS by in vivo base editing","volume":"28","author":"Lim","year":"2020","journal-title":"Mol Ther"},{"issue":"4","key":"10.1007\/s13311-022-01285-w_bib140","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1172\/JCI123931","article-title":"Virus-mediated delivery of antibody targeting TAR DNA-binding protein-43 mitigates associated neuropathology","volume":"129","author":"Pozzi","year":"2019","journal-title":"J Clin Invest"},{"issue":"14","key":"10.1007\/s13311-022-01285-w_bib141","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.omtn.2019.01.010","article-title":"Artificial microRNAs targeting C9orf72 can reduce accumulation of intra-nuclear transcripts in ALS and FTD patients","volume":"1","author":"Martier","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"issue":"16","key":"10.1007\/s13311-022-01285-w_bib142","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.001","article-title":"Targeting RNA-mediated toxicity in C9orf72 ALS and\/or FTD by RNAi-based gene therapy","volume":"11","author":"Martier","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"10.1007\/s13311-022-01285-w_bib143","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.cell.2009.01.042","article-title":"Regulation of translation initiation in eukaryotes: mechanisms and biological targets","volume":"136","author":"Sonenberg","year":"2009","journal-title":"Cell"},{"issue":"31","key":"10.1007\/s13311-022-01285-w_bib144","doi-asserted-by":"crossref","first-page":"18591","DOI":"10.1073\/pnas.2005748117","article-title":"Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS\/FTD mice","volume":"117","author":"Zu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1007\/s13311-022-01285-w_bib145","doi-asserted-by":"crossref","first-page":"5672","DOI":"10.1038\/s41598-022-07746-8","article-title":"Dual-gRNA approach with limited off-target effect corrects C9ORF72 repeat expansion in vivo","volume":"12","author":"Piao","year":"2022","journal-title":"Sci Rep"},{"issue":"10","key":"10.1007\/s13311-022-01285-w_bib146","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3389\/fneur.2019.00835","article-title":"Past and future of neurotrophic growth factors therapies in ALS: from single neurotrophic growth factor to stem cells and human platelet lysates","volume":"2","author":"Gouel","year":"2019","journal-title":"Front Neurol"},{"issue":"4","key":"10.1007\/s13311-022-01285-w_bib147","first-page":"32","article-title":"Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?","volume":"11","author":"Henriques","year":"2010","journal-title":"Front Neurosci"},{"issue":"6","key":"10.1007\/s13311-022-01285-w_bib148","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/mt.2008.60","article-title":"Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity","volume":"16","author":"Dodge","year":"2008","journal-title":"Mol Ther J Am Soc Gene Ther"},{"issue":"12","key":"10.1007\/s13311-022-01285-w_bib149","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/mt.2010.206","article-title":"AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice","volume":"18","author":"Dodge","year":"2010","journal-title":"Mol Ther"},{"issue":"1","key":"10.1007\/s13311-022-01285-w_bib150","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s12035-016-0335-z","article-title":"Intramuscular delivery of scAAV9-hIGF1 prolongs survival in the hSOD1G93A ALS mouse model via upregulation of D-amino acid oxidase","volume":"55","author":"Lin","year":"2018","journal-title":"Mol Neurobiol"},{"issue":"139","key":"10.1007\/s13311-022-01285-w_bib151","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.brainresbull.2018.02.015","article-title":"Systemic administration of scAAV9-IGF1 extends survival in SOD1G93A ALS mice via inhibiting p38 MAPK and the JNK-mediated apoptosis pathway","volume":"1","author":"Wang","year":"2018","journal-title":"Brain Res Bull"},{"issue":"16","key":"10.1007\/s13311-022-01285-w_bib152","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1523\/JNEUROSCI.22-16-06920.2002","article-title":"Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis","volume":"22","author":"Wang","year":"2002","journal-title":"J Neurosci Off J Soc Neurosci."},{"issue":"4","key":"10.1007\/s13311-022-01285-w_bib153","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/gt.2017.9","article-title":"Systemic injection of AAV9-GDNF provides modest functional improvements in the SOD1G93A ALS rat but has adverse side effects","volume":"24","author":"Thomsen","year":"2017","journal-title":"Gene Ther"},{"issue":"2","key":"10.1007\/s13311-022-01285-w_bib154","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s13311-021-01025-6","article-title":"Specific expression of glial-derived neurotrophic factor in muscles as gene therapy strategy for amyotrophic lateral sclerosis","volume":"18","author":"M\u00f2dol-Caballero","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1007\/s13311-022-01285-w_bib155","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/mt.2010.271","article-title":"CNS-targeted viral delivery of G-CSF in an animal model for ALS: improved efficacy and preservation of the neuromuscular unit","volume":"19","author":"Henriques","year":"2011","journal-title":"Mol Ther"},{"issue":"7","key":"10.1007\/s13311-022-01285-w_bib156","first-page":"14","article-title":"Intrathecal delivery of recombinant AAV1 encoding hepatocyte growth factor improves motor functions and protects neuromuscular system in the nerve crush and SOD1-G93A transgenic mouse models","volume":"12","author":"Lee","year":"2019","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"10.1007\/s13311-022-01285-w_bib157","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.bbrc.2019.07.105","article-title":"Intramuscular delivery of HGF-expressing recombinant AAV improves muscle integrity and alleviates neurological symptoms in the nerve crush and SOD1-G93A transgenic mouse models","volume":"517","author":"Lee","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"issue":"29","key":"10.1007\/s13311-022-01285-w_bib158","doi-asserted-by":"crossref","first-page":"14755","DOI":"10.1073\/pnas.1904665116","article-title":"AAV2\/9-mediated overexpression of MIF inhibits SOD1 misfolding, delays disease onset, and extends survival in mouse models of ALS","volume":"116","author":"Leyton-Jaimes","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1007\/s13311-022-01285-w_bib159","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.stem.2019.04.016","article-title":"Mir-17\u223c92 confers motor neuron subtype differential resistance to ALS-associated degeneration","volume":"25","author":"Tung","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"8","key":"10.1007\/s13311-022-01285-w_bib160","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/humu.20763","article-title":"A meta-analysis of nonsense mutations causing human genetic disease","volume":"29","author":"Mort","year":"2008","journal-title":"Hum Mutat"},{"issue":"4","key":"10.1007\/s13311-022-01285-w_bib161","doi-asserted-by":"crossref","first-page":"e1641","DOI":"10.1002\/wrna.1641","article-title":"Therapeutic promise of engineered nonsense suppressor tRNAs","volume":"12","author":"Porter","year":"2021","journal-title":"Wiley Interdiscip Rev RNA"},{"issue":"7905","key":"10.1007\/s13311-022-01285-w_bib162","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41586-022-04533-3","article-title":"AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice","volume":"604","author":"Wang","year":"2022","journal-title":"Nature"},{"key":"10.1007\/s13311-022-01285-w_bib163","doi-asserted-by":"crossref","unstructured":"Torkzaban B, Kawalerski R, Coller J. Development of a tethered mRNA amplifier to increase protein expression. Biotechnol J. 2022:2200214.","DOI":"10.1002\/biot.202200214"},{"issue":"5","key":"10.1007\/s13311-022-01285-w_bib164","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nn.4000","article-title":"Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia","volume":"18","author":"Freischmidt","year":"2015","journal-title":"Nat Neurosci"},{"issue":"6","key":"10.1007\/s13311-022-01285-w_bib165","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41582-021-00487-8","article-title":"Non-neuronal cells in amyotrophic lateral sclerosis \u2014 from pathogenesis to biomarkers","volume":"17","author":"Vahsen","year":"2021","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"10.1007\/s13311-022-01285-w_bib166","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/jnnp.2009.183525","article-title":"Incidence of amyotrophic lateral sclerosis in Europe","volume":"81","author":"Logroscino","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.1007\/s13311-022-01285-w_bib167","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3390\/genes12121935","article-title":"Juvenile amyotrophic lateral sclerosis: a review","volume":"12","author":"Lehky","year":"2021","journal-title":"Genes"},{"issue":"1","key":"10.1007\/s13311-022-01285-w_bib168","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/ng0595-61","article-title":"Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase","volume":"10","author":"Andersen","year":"1995","journal-title":"Nat Genet"},{"issue":"417","key":"10.1007\/s13311-022-01285-w_bib169","doi-asserted-by":"crossref","first-page":"117054","DOI":"10.1016\/j.jns.2020.117054","article-title":"Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis","volume":"15","author":"Richards","year":"2020","journal-title":"J Neurol Sci"},{"issue":"2","key":"10.1007\/s13311-022-01285-w_bib170","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/bpa.12350","article-title":"The role of skeletal muscle in amyotrophic lateral sclerosis","volume":"26","author":"Loeffler","year":"2016","journal-title":"Brain Pathol"},{"key":"10.1007\/s13311-022-01285-w_bib171","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2022.01.008","article-title":"Non-viral vectors for RNA delivery","volume":"342","author":"Yan","year":"2022","journal-title":"J Control Release Off J Control Release Soc"},{"issue":"39","key":"10.1007\/s13311-022-01285-w_bib172","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.1605731113","article-title":"Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy","volume":"113","author":"Hammond","year":"2016","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"10.1007\/s13311-022-01285-w_bib173","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41591-021-01664-4","article-title":"AAV gene therapy for Tay-Sachs disease","volume":"28","author":"Flotte","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"10.1007\/s13311-022-01285-w_bib174","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol Ther"},{"issue":"3","key":"10.1007\/s13311-022-01285-w_bib175","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10.1007\/s13311-022-01285-w_bib176","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41591-019-0344-3","article-title":"Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy","volume":"25","author":"Nelson","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"10.1007\/s13311-022-01285-w_bib177","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nbt.3081","article-title":"Efficient delivery of genome-editing proteins in vitro and in vivo","volume":"33","author":"Zuris","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1007\/s13311-022-01285-w_bib178","doi-asserted-by":"crossref","unstructured":"Duan L, Ouyang K, Xu X, Xu L, Wen C, Zhou X, et al. Nanoparticle delivery of CRISPR\/Cas9 for genome editing. Front Genet [Internet]. 2021 [cited 2022 Apr 26];12. Available from: https:\/\/www.frontiersin.org\/article\/10.3389\/fgene.2021.673286.","DOI":"10.3389\/fgene.2021.673286"},{"issue":"3","key":"10.1007\/s13311-022-01285-w_bib179","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/mt.2011.292","article-title":"Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles","volume":"20","author":"Mueller","year":"2012","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"10.1007\/s13311-022-01285-w_bib180","unstructured":"Wave Life Sciences Ltd. A multicenter, randomized, double-blind, placebo-controlled, phase 1b\/2a study of WVE-004 administered intrathecally to patients with C9orf72-associated amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD) [Internet]. clinicaltrials.gov; 2022 Mar [cited 2022 May 2]. Report No.: NCT04931862. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04931862."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01285-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01285-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01285-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:48:07Z","timestamp":1761806887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923010747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":180,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1878747923010747"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01285-w","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Approaches to Gene Modulation Therapy for ALS","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01285-w","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}